VENLO, The Netherlands, June 3, 2016 /PRNewswire/ --

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced another extension of the Offer Period for the acquisition of Exiqon A/S, a world leader in RNA technology. On 18 April 2016, QIAGEN N.V. had published a conditional, voluntary public tender offer for the shares in Exiqon A/S, in which the shareholders were offered a cash amount of DKK 18 for each share held in Exiqon A/S. This Offer Period had been extended on 19 May 2016, its terms and conditions remained unchanged. In accordance with the Offer, the extended Offer Period expired yesterday on 2 June 2016 at 23.59 (CET).

QIAGEN N.V. has in total received acceptances from shareholders in Exiqon A/S representing 89.21 % of the share capital and voting rights in Exiqon A/S. In accordance with the conditions of the Offer and section 9 of the Danish Takeover Order no. 562 of 2 June 2014 QIAGEN N.V. has decided to extend the Offer Period one more time. Consequently, the Offer is valid as of 19 April 2016 and expires on 20 June 2016 at 23:59 (CET).

"We have made a compelling and fair offer that is not only appreciated by Exiqon's board of directors and its largest shareholders", said Peer Schatz, CEO of QIAGEN N.V. "During the first extension period, additional retail shareholders also have recognized that the offer values the company appropriately and have tendered their shares. We extend the offer one more time and trust that in the end we will reach the 90 % acceptance rate necessary to complete the transaction."

Click here for full press release

Investor Relations
John Gilardi
+49-2103-29-11711
e-mail: ir@QIAGEN.com

Public Relations
Dr. Thomas Theuringer
+49-2103-29-11826
e-mail: pr@QIAGEN.com

SOURCE QIAGEN N.V.